Bluejay Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
Bluejay Therapeutics logo

Bluejay Therapeutics

NicheLife Sciences & BioTech

Liver Disease & Hepatitis B Therapeutics

Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B and liver diseases; raised over $100M; lead candidate BJT-778 entered clinical trials;

AI VisibilityBeta
Overall Score
D35
Category Rank
#131 of 198
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
36
Gemini
35

About

Bluejay Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Redwood City, California. The company is focused on developing innovative therapies for chronic liver diseases, with hepatitis B virus (HBV) infection as its primary indication. Chronic HBV is a significant unmet medical need affecting an estimated 296 million people worldwide; while existing antivirals like tenofovir and entecavir suppress the virus effectively, they do not achieve a functional cure and require lifelong treatment. Bluejay''s therapeutic programs aim to achieve functional cure — defined as durable suppression of HBV surface antigen (HBsAg) after treatment ends — by targeting viral replication mechanisms and immune restoration simultaneously.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#131
Category Rank
#11
85
AI Consensus
68
stable
Trend
stable
35
ChatGPT
71
36
Perplexity
68
35
Gemini
80
30
Claude
77
32
Grok
69

Key Details

Category
Liver Disease & Hepatitis B Therapeutics
AI-Enabled Precision Medicine
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.